Case Studies

WEP Clinical is committed to supporting companies in the pharmaceutical industry to help make much-needed medicines available to patients, physicians, hospitals and R&D centers.

EAP
PA-NPP
Market Access
Nursing

Expanded Access

Check out our case studies to the right, or click below to learn more about our Expanded Access services.

Learn More

HELPING A SPONSOR COLLECT DATA IN AN EXPANDED ACCESS PROGRAM TO SUPPORT CLINICAL TRIAL DATA

Therapeutic Area: Oncology Clinical Trial Phase: Phase 2

ACTING AS A STRATEGIC ACCESS PROGRAM PARTNER – GOING BEYOND THE STANDARD VENDOR APPROACH

Therapeutic Area: Serious Pulmonary Conditions Clinical Trial Phase: Phase 3

SUPPORTING A BIOTECHNOLOGY COMPANY WITH A GLOBAL POST-TRIAL ACCESS PROGRAM

Therapeutic Area: Rare Disease Clinical Trial Phase: Phase 3

HOW STRONG PROJECT MANAGEMENT DELIVERED A SUCCESSFUL CELL THERAPY EAP

Therapeutic Area: Cell therapy Clinical Trial Phase: Phase 2

HELPING A SPONSOR PROVIDE ACCESS TO INVESTIGATIONAL DRUG OUTSIDE OF CLINICAL TRIAL

Condition: Rare, progressive autoimmune condition Clinical Trial Phase: Completed Phase 3

HELPING A SPONSOR SCALE UP AN EAP TO FULFILL INCREASE IN DEMAND FOR PROMISING ONCOLOGY PRODUCT

Therapeutic Area: Oncology Clinical Trial Phase: Phase 3

USING EXPANDED ACCESS AS AN ALTERNATIVE TO AN OPEN LABEL EXTENSION (OLE) STUDY

Condition: Rare Gastrointestinal Tumors Clinical Trial Phase: Phase 2

HELPING A SPONSOR RESCUE AN EXISTING EAP FROM ANOTHER VENDOR

Condition: Debilitating neurological disorder Clinical Trial Phase: Completed Phase 3

RAPIDLY SCALING AN EAP TO FULFIL UNMET CLINICAL NEED FOR PATIENTS WITH LIFE-THREATENING SEIZURES

Therapeutic Area: Rare Disease Clinical Trial Phase: Completed Phase 3

EXPERTLY NAVIGATING REGULATORY COMPLEXITIES DURING AN EXPANDED ACCESS PROGRAM

Therapeutic Area: Rare Disease Clinical Trial Phase: Phase 3

Post-Approval Named Patient

Check out our case studies to the right, or click below to learn more about our PA-NPP services.

Learn More

Providing a Paid-For Post-Approval Named Patient Program

Condition: Rare autoimmune disorder Approved in: US

USING A PA-NPP TO CREATE ACCESS FOR A CANADIAN-APPROVED PRODUCT IN EUROPE

Condition: Genetic metabolic disorder Approved in: Canada

SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY

Condition: Rare autoimmune disease Approved in: US and Europe

PROVIDING SITE TRAINING AS PART OF A PA-NPP FOR A SPECIALIZED PRODUCT

Condition: Pediatric cancer Approved in: US

Market Access

Check out our case studies to the right, or click below to learn more about our Market Access services.

Learn More

SUPPORTING A MEDICINE THROUGHOUT THE DEVELOPMENT JOURNEY

Condition: Rare autoimmune disease Approved in: US and Europe

PROVIDING DRUG IN FRANCE THROUGH REVISED LEGISLATION FOR AAC COMPASSIONATE USE ACCESS

Condition: Serious, debilitating condition Approved in: US

PROVIDING EU5 MARKET ACCESS STRATEGY AND REIMBURSEMENT SUPPORT

Treatment Type: Emergency medicine Approved in: US

The VALUE OF WORKING WITH WEP TO PROVIDE EARLY ACCESS IN FRANCE

Treatment Type: Infectious Disease Clinical Trial Phase: Phase 3

Nursing Solutions

To learn more about our nursing services, click the button below.

Learn More

THE VALUE OF THE WEP FLYING NURSE MODEL FOR A COMPLEX CLINICAL TRIAL WITH TIGHT TURNAROUND TIMES

Condition: Life-threatening Medical Emergency Clinical Trial Phase: Phase 2/3

HOW WEP's COUNTRY COORDINATOR TEAM HELPS SUCCESSFULLY DELIVER AN ONGOING MOBILE NURSING SOLUTION

Condition: Rare Neurodegenerative Disease Clinical Trial Phase: Phase 3

UTILIZING A MOBILE NURSING SOLUTION TO HELP ENHANCE PATIENT RECRUITMENT IN A PEDIATRIC CLINICAL TRIAL

Condition: Rare Genetic Disease Clinical Trial Phase: Phase 3

PROVIDING CLINICAL HOMECARE NURSING SERVICES FOR VACCINE STUDY IN THE UK

Condition: Infectious Disease Clinical Trial Phase: Phase 3

SUPPORTING A SPONSOR WITH HOME HEALTHCARE SERVICES FOR AN ORAL CANCER TREATMENT CLINICAL TRIAL

Condition: Solid Tumors Clinical Trial Phase: Phase 2

PROVIDING SITE TRAINING AS PART OF A PA-NPP FOR A SPECIALIZED PRODUCT

Condition: Pediatric cancer Approved in: US

NEED MORE INFORMATION?

Contact Us